U.S., Feb. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07426484) titled 'Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy' on Feb. 02.
Brief Summary: This is study is to evaluate the safety and efficacy of cosibelimab in special populations with advanced cutaneous squamous cell carcinoma (CSCC).
The name of the drug involved in this research study is:
-cosibelimab (a type of an anti-PD-L1 antibody)
Study Start Date: July, 2026
Study Type: INTERVENTIONAL
Condition:
Cutaneous Squamous Cell Carcinoma
Skin Cancer
Intervention:
DRUG: Cosibelimab
Anti-PD-L1 antibody, single dose vials, via intravenous (into the vein) infusion per protocol
DRUG: Prednisone
Corticoster...